Heart Failure With Preserved or Reduced Ejection Fraction in Patients Treated With Peritoneal Dialysis

被引:40
|
作者
Wang, Angela Yee-Moon [1 ]
Wang, Mei [1 ]
Lam, Christopher Wai-Kei [2 ,3 ]
Chan, Iris Hiu-Shuen [2 ]
Lui, Siu-Fai [1 ]
Sanderson, John E. [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China
[3] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, Taipa, Peoples R China
关键词
Heart failure; preserved ejection fraction; peritoneal dialysis; mortality; cardiovascular outcomes; STAGE RENAL-DISEASE; LEFT ATRIAL VOLUME; TROPONIN-T; NATRIURETIC PEPTIDE; CARDIOVASCULAR CONGESTION; CARDIAC-HYPERTROPHY; SYSTOLIC FUNCTION; PROGNOSTIC VALUE; RISK; DEATH;
D O I
10.1053/j.ajkd.2012.12.030
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Heart failure is one of the most frequent complications in dialysis patients. However, little is known of the significance of the entity "heart failure with preserved ejection fraction" (HFPEF) in this population. This study aimed to determine the prevalence, clinical profiles, and long-term outcomes of peritoneal dialysis patients with HFPEF. Study Design: Prospective cohort study. Setting & Participants: 220 patients treated with peritoneal dialysis were recruited from a university teaching hospital in Hong Kong. Predictor: Heart failure was defined clinically based on the presence of: (1) symptoms and signs, including dyspnea, increased jugular venous pressure, and basal crepitations; (2) radiographic evidence of pulmonary venous congestion or interstitial edema; and (3) resolution of symptoms, signs, and radiographic changes with hypertonic peritoneal dialysis exchanges. Based on a combination of clinical history of heart failure and echocardiography-derived ejection fraction, patients were classified as having no heart failure, HFPEF, and heart failure with reduced ejection fraction (HFREF). Outcomes: All-cause mortality, cardiac death, heart failure, and fatal or nonfatal cardiovascular events. Measurements: All patients underwent 2-dimensional echocardiography and tissue Doppler imaging at baseline and were followed up prospectively for clinical events for 4 years. Results: 86 (39%) patients had heart failure, of whom 54.7% had preserved ejection fraction >= 50% and 45.3% had reduced ejection fraction <50%. Patients with HFPEF were intermediate between those with no heart failure and those with HFREF in terms of blood pressure, prevalence of coronary artery disease, diabetes, cardiac biomarkers, left ventricular mass, volume, and ratio of early mitral inflow velocity to peak mitral annulus velocity. In the multivariable Cox regression analysis, patients with HFPEF showed an increased adjusted HR for cardiac death (2.57; 95% CI, 1.20-5.50), heart failure (HR, 2.25; 95% CI, 1.28-3.96), and fatal or nonfatal cardiovascular event (HR, 2.01; 95% CI, 1.26-3.21) compared with those with no heart failure, but the risk was lower compared with those with HFREF. Limitations: The study included prevalent peritoneal dialysis patients and may introduce survival bias. Conclusions: HFPEF is common in peritoneal dialysis patients (similar to 55% of all heart failure) and is associated with increased risk of mortality and adverse cardiovascular outcomes compared with those with no heart failure, although the risk was lower than in patients with HFREF. This entity needs to be more recognized in peritoneal dialysis patients. (c) 2013 by the National Kidney Foundation, Inc.
引用
收藏
页码:975 / 983
页数:9
相关论文
共 50 条
  • [41] Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction
    Kiuchi, Shunsuke
    Hisatake, Shinji
    Kabuki, Takayuki
    Oka, Takashi
    Dobashi, Shintaro
    Fujii, Takahiro
    Ikeda, Takanori
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2020, 42 (02) : 110 - 117
  • [42] Right ventricular function in patients with preserved and reduced ejection fraction heart failure
    Puwanant, Sarinya
    Priester, Tiffany C.
    Mookadam, Farouk
    Bruce, Charles J.
    Redfield, Margaret M.
    Chandrasekaran, Krishnaswamy
    EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY, 2009, 10 (06): : 733 - 737
  • [43] Comparison Of Hospital Outcomes Between Heart Failure With Reduced Ejection Fraction And Heart Failure With Preserved Ejection Fraction Among Patients With Anemia
    Mir, Junaid
    AL Ahmad, Majd
    Khalil, Ayesha
    AL Ahmad, Anas
    Malik, Adnan
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [44] Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction
    Tromp, Jasper
    Lim, Shir Lynn
    Tay, Wan Ting
    Teng, Tiew-Hwa Katherine
    Chandramouli, Chanchal
    Ouwerkerk, Wouter
    Wander, Gupreet S.
    Sawhney, Jitendra P. S.
    Yap, Jonathan
    MacDonald, Michael R.
    Ling, Lieng Hsi
    Sattar, Naveed
    McMurray, John J. V.
    Richards, A. Mark
    Anand, Inder
    Lam, Carolyn S. P.
    DIABETES CARE, 2019, 42 (09) : 1792 - 1799
  • [45] Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction
    Rossitto, Giacomo
    Mary, Sheon
    McAllister, Christine
    Neves, Karla Bianca
    Haddow, Laura
    Rocchiccioli, John Paul
    Lang, Ninian Nicholas
    Murphy, Clare Louise
    Touyz, Rhian Merry
    Petrie, Mark Colquhoun
    Delles, Christian
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (24) : 2817 - 2829
  • [46] MYOCARDIAL FIBROSIS IN HEART FAILURE WITH REDUCED AND PRESERVED EJECTION FRACTION
    Shchekochikhin, Dmitri
    Solomakhina, Nina
    Warshavsky, Anatoli
    Belenkov, Yuri
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E289 - E289
  • [47] Mouse Models of Heart Failure with Preserved or Reduced Ejection Fraction
    Noll, Natalie A.
    Lal, Hind
    Merryman, W. David
    AMERICAN JOURNAL OF PATHOLOGY, 2020, 190 (08): : 1596 - 1608
  • [48] Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction
    Alcaide, Pilar
    Kallikourdis, Marinos
    Emig, Ramona
    Prabhu, Sumanth D.
    CIRCULATION RESEARCH, 2024, 134 (12) : 1752 - 1766
  • [49] Candidate biomarkers in heart failure with reduced and preserved ejection fraction
    Sinning, Christoph
    Zengin, Elvin
    Zeller, Tanja
    Schnabel, Renate B.
    Blankenberg, Stefan
    Westermann, Dirk
    BIOMARKERS, 2015, 20 (04) : 258 - 265
  • [50] Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
    Solomon, S. D.
    McMurray, J. J., V
    Claggett, B.
    de Boer, R. A.
    DeMets, D.
    Hernandez, A. F.
    Inzucchi, S. E.
    Kosiborod, M. N.
    Lam, C. S. P.
    Martinez, F.
    Shah, S. J.
    Desai, A. S.
    Jhund, P. S.
    Belohlavek, J.
    Chiang, C-E
    Borleffs, C. J. W.
    Comin-Colet, J.
    Dobreanu, D.
    Drozdz, J.
    Fang, J. C.
    Alcocer-Gamba, M. A.
    Al Habeeb, W.
    Han, Y.
    Cabrera Honorio, J. W.
    Janssens, S. P.
    Katova, T.
    Kitakaze, M.
    Merkely, B.
    O'Meara, E.
    Saraiva, J. F. K.
    Tereshchenko, S. N.
    Thierer, J.
    Vaduganathan, M.
    Vardeny, O.
    Verma, S.
    Pham, V. N.
    Wilderang, U.
    Zaozerska, N.
    Bachus, E.
    Lindholm, D.
    Petersson, M.
    Langkilde, A. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, : 1089 - 1098